GenSpera (OTCQB:GNSZ) to Present Lead
Drug Candidate Mipsagargin at 2nd Global Life Sciences Conference in Warsaw,
Poland
SAN ANTONIO - September 30, 2014 (Investorideas.com Biotech
Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for
the treatment of cancer, announces Craig Dionne, PhD, GenSpera's CEO, will be
presenting at the upcoming 2nd Global Life Sciences Conference on October 2,
2014, in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange.
The
conference is sponsored by WedBush Europe and WDM Capital. Some of the Central
and Eastern European leading life science institutional investors, fund
managers and analysts will gather in Warsaw to discuss and assess new
investment opportunities. More info: http://lscwarsaw.com.
Dr. Dionne will be giving a corporate
presentation of the company's lead drug candidate, mipsagargin (G-202),
currently in Phase II clinical trials for hepatocellular carcinoma (liver
cancer) and glioblastoma (brain cancer).
A copy of the presentation will be made
available on the Company's website, following the conference.
GenSpera has recently announced several key
milestones and more information can be found by reviewing the press releases on
the company's website http://www.genspera.com.
*United States Patent and Trademark Office
(USPTO) issuance of patents US 8,822,406
"Tumor
Activated Prodrugs" and US 8,772,226 B2 "Methods and compositions for
the detection of cancer"
*Generic name "mipsagargin" for
lead drug candidate G-202 per recommendation by World Health Organization's
(WHO) International Nonproprietary Name (INN) group
*GenSpera Wins Summary Judgment in Mhaka
Litigation
Read this release
in full at http://www.investorideas.com/CO/GNSZ/news/2014/09301.asp
About GenSpera
GenSpera's technology platform combines a
powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system
that provides for the targeted release of drug candidates within a tumor.
Unlike typical chemotherapeutic agents, thapsigargin results in cell death
irrespective of the rate of cell division, which may provide an effective
approach to kill both fast- and slow-growing cancers. GenSpera's lead drug
candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high
levels in the vasculature of liver and glioblastoma cancers and in the
vasculature of almost all other solid tumors. Mipsagargin is therefore expected
to have potential efficacy in a wide variety of tumor types.
For more information, please visit the
company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Cautionary Statement Regarding Forward
Looking Information
This news release may contain
forward-looking statements. Investors are cautioned that statements in this
press release regarding potential applications of GenSpera's technologies
constitute forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development and
commercialization of potential products, uncertainty of clinical trial results
or regulatory approvals or clearances, need for future capital, dependence upon
collaborators and maintenance of our intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential factors that
could affect our results and other risks and uncertainties will be detailed
from time to time in GenSpera's periodic reports filed with the Securities and
Exchange Commission.
Contact:
Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Craig Dionne, PhD, CEO
GenSpera, Inc.
+1-210-479-8112
Media: Dawn Van Zant
800-665-0411
800-665-0411
Disclaimer/Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera
(GNSZ) has engaged Investor Ideas for PR and news publication effective
June 18, 2014 (compensation of five thousand per month and average of eleven
thousand five hundred 144 shares per month)
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
No comments:
Post a Comment